KRAS and colorectal carcinoma: Previous genomic characterization of this cell line showed mutation in KRAS and lack of mutations in MMR, POLD1/POLE, and BRAF genes, suggesting that this cell line is a better model for non-hypermutated/MSS human CRC tumors22.